New drug duo aims to reboot immune system against tough lung cancers
NCT ID NCT07322341
First seen Jan 09, 2026 · Last updated Apr 22, 2026 · Updated 10 times
Summary
This study is testing whether a new drug, SX-682, combined with an existing immunotherapy drug (atezolizumab), can help control advanced non-small cell lung cancer that has worsened after standard chemotherapy and immunotherapy. It aims to see if this combination can help the patient's own immune system better recognize and attack the cancer. The trial is for adults whose cancer has spread or returned after prior treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.